{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:26:02Z","timestamp":1793852762711,"version":"4.6.1"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["218471\/Z\/19\/Z]"],"award-info":[{"award-number":["218471\/Z\/19\/Z]"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["227167\/A\/23\/Z"],"award-info":[{"award-number":["227167\/A\/23\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-68335-1","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:02:55Z","timestamp":1768903375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sero-genomic evidence for occult mpox exposure in healthy Nigerian adults"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9703-8264","authenticated-orcid":false,"given":"Adam","family":"Abdullahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifeanyi","family":"Omah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Kassanjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fehintola","family":"Ige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Edun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Osawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine K.","family":"Koofhethile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Wisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezenwa James","family":"Onyemata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyth","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-2920","authenticated-orcid":false,"given":"Onikepe","family":"Folarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniekwe M.","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ummasalma Aliyu","family":"Saulawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Ceron-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaezi","family":"Okpokoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8959-5175","authenticated-orcid":false,"given":"Anise","family":"Happi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-5219","authenticated-orcid":false,"given":"Rosemary","family":"Audu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sani H.","family":"Aliyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manhattan","family":"Charurat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3056-6705","authenticated-orcid":false,"given":"Christian","family":"Happi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babatunde Lawal","family":"Salako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Doffinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alash\u2019le","family":"Abimiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9751-1808","authenticated-orcid":false,"given":"Ravindra K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"68335_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41392-023-01675-2","volume":"8","author":"J Lu","year":"2023","unstructured":"Lu, J. et al. Mpox (formerly monkeypox): pathogenesis, prevention and treatment. Signal Transduct. Target Ther. 8, 458 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"68335_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41577-022-00775-4","volume":"22","author":"F-M Lum","year":"2022","unstructured":"Lum, F.-M. et al. Monkeypox: disease epidemiology, host immunity and clinical interventions. Nat. Rev. Immunol. 22, 597\u2013613 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"68335_CR3","doi-asserted-by":"publisher","first-page":"e3001769","DOI":"10.1371\/journal.pbio.3001769","volume":"20","author":"C Happi","year":"2022","unstructured":"Happi, C. et al. Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus. PLoS Biol. 20, e3001769 (2022).","journal-title":"PLoS Biol."},{"key":"68335_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4269\/ajtmh.24-0606","volume":"112","author":"A Zumla","year":"2025","unstructured":"Zumla, A. et al. The 2024 public health emergency of international concern: a global failure to control Mpox. Am. J. Trop. Med Hyg. 112, 17\u201320 (2025).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"68335_CR5","doi-asserted-by":"publisher","unstructured":"Djuicy, D. D. et al. Molecular epidemiology of recurrent zoonotic transmission of mpox virus in West Africa. medRxiv 2024.06.18.24309115 https:\/\/doi.org\/10.1101\/2024.06.18.24309115 (2024).","DOI":"10.1101\/2024.06.18.24309115"},{"key":"68335_CR6","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/s41591-023-02456-8","volume":"29","author":"N Ndodo","year":"2023","unstructured":"Ndodo, N. et al. Distinct monkeypox virus lineages co-circulating in humans before 2022. Nat. Med 29, 2317\u20132324 (2023).","journal-title":"Nat. Med"},{"key":"68335_CR7","first-page":"595","volume":"382","author":"\u00c1 O\u2019Toole","year":"2023","unstructured":"O\u2019Toole, \u00c1 et al. APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016. Science (1979) 382, 595\u2013600 (2023).","journal-title":"Science (1979)"},{"key":"68335_CR8","doi-asserted-by":"publisher","unstructured":"Parker, E. et al. Genomics reveals zoonotic and sustained human Mpox spread in West Africa. Nature https:\/\/doi.org\/10.1038\/s41586-025-09128-2 (2025).","DOI":"10.1038\/s41586-025-09128-2"},{"key":"68335_CR9","doi-asserted-by":"publisher","first-page":"e0010141","DOI":"10.1371\/journal.pntd.0010141","volume":"16","author":"EM Bunge","year":"2022","unstructured":"Bunge, E. M. et al. The changing epidemiology of human monkeypox\u2014A potential threat? A systematic review. PLoS Negl. Trop. Dis. 16, e0010141 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"68335_CR10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1473-3099(19)30294-4","volume":"19","author":"A Yinka-Ogunleye","year":"2019","unstructured":"Yinka-Ogunleye, A. et al. Outbreak of human monkeypox in Nigeria in 2017\u201318: a clinical and epidemiological report. Lancet Infect. Dis. 19, 872\u2013879 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"68335_CR11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-022-01907-y","volume":"28","author":"J Isidro","year":"2022","unstructured":"Isidro, J. et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat. Med. 28, 1569\u20131572 (2022).","journal-title":"Nat. Med."},{"key":"68335_CR12","doi-asserted-by":"publisher","unstructured":"Sumner, R. P. et al. Attenuation of the 2022 global outbreak monkeypox virus relative to its clade IIb ancestor. bioRxiv 2025.02.27.640535 https:\/\/doi.org\/10.1101\/2025.02.27.640535 (2025).","DOI":"10.1101\/2025.02.27.640535"},{"key":"68335_CR13","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3201\/eid2909.230541","volume":"29","author":"D Mizushima","year":"2023","unstructured":"Mizushima, D. et al. Prevalence of asymptomatic mpox among men who have sex with men, Japan, January\u2013March 2023. Emerg. Infect. Dis. J. 29, 1872 (2023).","journal-title":"Emerg. Infect. Dis. J."},{"key":"68335_CR14","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/S2666-5247(22)00379-2","volume":"4","author":"S Accordini","year":"2023","unstructured":"Accordini, S., Cordioli, M., Pomari, E., Tacconelli, E. & Castilletti, C. People with asymptomatic or unrecognised infection potentially contribute to monkeypox virus transmission. Lancet Microbe 4, e209 (2023).","journal-title":"Lancet Microbe"},{"key":"68335_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40490-9","volume":"14","author":"C Agust\u00ed","year":"2023","unstructured":"Agust\u00ed, C. et al. Self-sampling monkeypox virus testing in high-risk populations, asymptomatic or with unrecognized Mpox, in Spain. Nat. Commun. 14, 5998 (2023).","journal-title":"Nat. Commun."},{"key":"68335_CR16","doi-asserted-by":"publisher","first-page":"107009","DOI":"10.1016\/j.ijid.2024.107009","volume":"143","author":"S Edouard","year":"2024","unstructured":"Edouard, S. et al. Incidental diagnosis of mpox virus infection in patients undergoing sexually transmitted infection screening\u2014findings from a study in France. Int. J. Infect. Dis. 143, 107009 (2024).","journal-title":"Int. J. Infect. Dis."},{"key":"68335_CR17","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1038\/s41591-022-02004-w","volume":"28","author":"I De Baetselier","year":"2022","unstructured":"De Baetselier, I. et al. Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium. Nat. Med. 28, 2288\u20132292 (2022).","journal-title":"Nat. Med."},{"key":"68335_CR18","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.7326\/M22-2183","volume":"175","author":"VM Ferr\u00e9","year":"2022","unstructured":"Ferr\u00e9, V. M. et al. Detection of monkeypox virus in anorectal swabs from asymptomatic men who have sex with men in a sexually transmitted infection screening program in Paris, France. Ann. Intern Med 175, 1491\u20131492 (2022).","journal-title":"Ann. Intern Med"},{"key":"68335_CR19","doi-asserted-by":"publisher","first-page":"e856","DOI":"10.1016\/S2666-5247(23)00248-3","volume":"4","author":"B Hampel","year":"2023","unstructured":"Hampel, B. et al. Low prevalence of asymptomatic mpox in populations at high risk. Lancet Microbe 4, e856 (2023).","journal-title":"Lancet Microbe"},{"key":"68335_CR20","doi-asserted-by":"publisher","first-page":"e254305","DOI":"10.1136\/bcr-2022-254305","volume":"17","author":"M Mouro","year":"2024","unstructured":"Mouro, M. & Duque, V. Asymptomatic transmission of human mpox. BMJ Case Rep. 17, e254305 (2024).","journal-title":"BMJ Case Rep."},{"key":"68335_CR21","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/cid\/ciad414","volume":"77","author":"G Matusali","year":"2023","unstructured":"Matusali, G. et al. Asymptomatic Mpox virus infection in subjects presenting for MVA-BN vaccine. Clin. Infect. Dis. 77, 1483\u20131484 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"68335_CR22","doi-asserted-by":"publisher","first-page":"e70365","DOI":"10.1002\/jmv.70365","volume":"97","author":"S Henry","year":"2025","unstructured":"Henry, S. et al. Serological response to Mpox and direct virus detection in asymptomatic patient prior to the first diagnosed case: a retrospective study of the 2022 montpellier epidemic. J. Med Virol. 97, e70365 (2025).","journal-title":"J. Med Virol."},{"key":"68335_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/cid\/ciad145","volume":"77","author":"YP Ogale","year":"2023","unstructured":"Ogale, Y. P. et al. Evidence of Mpox Virus Infection Among Persons Without Characteristic Lesions or Rash Presenting for First Dose of JYNNEOS Vaccine\u2014District of Columbia, August 2022. Clin. Infect. Dis. 77, 298\u2013302 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"68335_CR24","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2666-5247(22)00259-2","volume":"4","author":"A Reda","year":"2023","unstructured":"Reda, A., El-Qushayri, A. E. & Shah, J. Asymptomatic monkeypox infection: a call for greater control of infection and transmission. Lancet Microbe 4, e15\u2013e16 (2023).","journal-title":"Lancet Microbe"},{"key":"68335_CR25","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S1473-3099(22)00664-8","volume":"23","author":"JC Taube","year":"2023","unstructured":"Taube, J. C., Rest, E. C., Lloyd-Smith, J. O. & Bansal, S. The global landscape of smallpox vaccination history and implications for current and future orthopoxvirus susceptibility: a modelling study. Lancet Infect. Dis. 23, 454\u2013462 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"68335_CR26","doi-asserted-by":"publisher","unstructured":"Ge, Y. et al. Associations between the 2022 global mpox outbreak and multifaceted factors: A multi-geographical retrospective study. One Health 101224 https:\/\/doi.org\/10.1016\/j.onehlt.2025.101224 (2025).","DOI":"10.1016\/j.onehlt.2025.101224"},{"key":"68335_CR27","doi-asserted-by":"publisher","first-page":"16262","DOI":"10.1073\/pnas.1005769107","volume":"107","author":"AW Rimoin","year":"2010","unstructured":"Rimoin, A. W. et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl. Acad. Sci. 107, 16262\u201316267 (2010).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"68335_CR28","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cell.2016.09.049","volume":"167","author":"I Gilchuk","year":"2016","unstructured":"Gilchuk, I. et al. Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Cell 167, 684\u2013694.e9 (2016).","journal-title":"Cell"},{"key":"68335_CR29","doi-asserted-by":"publisher","first-page":"eadg3540","DOI":"10.1126\/scitranslmed.adg3540","volume":"15","author":"AW Freyn","year":"2025","unstructured":"Freyn, A. W. et al. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci. Transl. Med 15, eadg3540 (2025).","journal-title":"Sci. Transl. Med"},{"key":"68335_CR30","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1016\/j.cell.2024.08.043","volume":"187","author":"EM Mucker","year":"2024","unstructured":"Mucker, E. M. et al. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell 187, 5540\u20135553.e10 (2024).","journal-title":"Cell"},{"key":"68335_CR31","first-page":"e02320","volume":"0","author":"L Mengjun","year":"2025","unstructured":"Mengjun, L. et al. Bispecific antibodies targeting MPXV A29 and B6 demonstrate efficacy against MPXV infection. J. Virol. 0, e02320\u2013e02324 (2025).","journal-title":"J. Virol."},{"key":"68335_CR32","doi-asserted-by":"crossref","unstructured":"Kong, T. et al. Single-chain A35R-M1R-B6R trivalent mRNA vaccines protect mice against both mpox virus and vaccinia virus. EBioMedicine 109, (2024).","DOI":"10.1016\/j.ebiom.2024.105392"},{"key":"68335_CR33","doi-asserted-by":"crossref","unstructured":"Tang, D. et al. Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge. Front Immunol Volume 14-2023, (2023).","DOI":"10.3389\/fimmu.2023.1203410"},{"key":"68335_CR34","doi-asserted-by":"publisher","unstructured":"Yu, H., Resch, W. & Moss, B. Poxvirus structural biology for application to vaccine design. Trends Immunol. https:\/\/doi.org\/10.1016\/j.it.2025.04.002 (2025).","DOI":"10.1016\/j.it.2025.04.002"},{"key":"68335_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000322101","volume":"37","author":"G Pauli","year":"2010","unstructured":"Pauli, G. et al. Orthopox viruses: Infections in humans. Transfus. Med. hemotherapy 37, 351\u2013364 (2010).","journal-title":"Transfus. Med. hemotherapy"},{"key":"68335_CR36","doi-asserted-by":"crossref","unstructured":"Manenti, A. et al. Evaluation of Monkeypox- and Vaccinia virus-neutralizing antibodies in human serum samples after vaccination and natural infection. Front Public Health Volume 11-2023, (2023).","DOI":"10.3389\/fpubh.2023.1195674"},{"key":"68335_CR37","unstructured":"WHO. Smallpox Eradication Programme - SEP (1966-1980). (2010)."},{"key":"68335_CR38","doi-asserted-by":"publisher","first-page":"D10","DOI":"10.1016\/j.vaccine.2011.04.008","volume":"29","author":"W Foege","year":"2011","unstructured":"Foege, W. Lessons and innovations from the West and Central African Smallpox Eradication Program. Vaccine 29, D10\u2013D12 (2011).","journal-title":"Vaccine"},{"key":"68335_CR39","unstructured":"WHO. Smallpox, Historic Milestone Underscores Urgent Need to Invest in Global Health Security and Universal Health Coverage."},{"key":"68335_CR40","doi-asserted-by":"publisher","unstructured":"Haeuser, E. et al. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet https:\/\/doi.org\/10.1016\/S0140-6736(25)01037-2 (2025).","DOI":"10.1016\/S0140-6736(25)01037-2"},{"key":"68335_CR41","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3201\/eid0706.010602","volume":"7","author":"S Rosenthal","year":"2001","unstructured":"Rosenthal, S., Merchlinsky, M., Kleppinger, C. & Goldenthal, K. Developing New Smallpox. Vaccines. Emerg. Infect. Dis. J. 7, 920 (2001).","journal-title":"Vaccines. Emerg. Infect. Dis. J."},{"key":"68335_CR42","unstructured":"Fenner, F. et al. Smallpox and Its Eradication (World Health Organization, 1988). https:\/\/iris.who.int\/items\/ba4ab312-1c43-4304-8235-969979499717."},{"key":"68335_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","volume":"84","author":"BL Jacobs","year":"2009","unstructured":"Jacobs, B. L. et al. Vaccinia virus vaccines: Past, present and future. Antivir. Res 84, 1\u201313 (2009).","journal-title":"Antivir. Res"},{"key":"68335_CR44","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nm1261","volume":"11","author":"Y Edghill-Smith","year":"2005","unstructured":"Edghill-Smith, Y. et al. Smallpox vaccine\u2013induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med 11, 740\u2013747 (2005).","journal-title":"Nat. Med"},{"key":"68335_CR45","first-page":"656","volume":"29","author":"I Sanz-Mu\u00f1oz","year":"2023","unstructured":"Sanz-Mu\u00f1oz, I. et al. Possible Mpox protection from smallpox. Vaccin.\u2013Generated Antibodies Older Adults. Emerg. Infect. Dis. J. 29, 656 (2023).","journal-title":"Vaccin.\u2013Generated Antibodies Older Adults. Emerg. Infect. Dis. J."},{"key":"68335_CR46","doi-asserted-by":"publisher","first-page":"e0157335","DOI":"10.1371\/journal.pone.0157335","volume":"11","author":"RN Greenberg","year":"2016","unstructured":"Greenberg, R. N. et al. A randomized, double-blind, placebo-controlled phase II trial investigating the safety and immunogenicity of modified vaccinia ankara smallpox vaccine (MVA-BN\u00ae) in 56-80-Year-Old Subjects. PLoS ONE 11, e0157335 (2016).","journal-title":"PLoS ONE"},{"key":"68335_CR47","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-022-02090-w","volume":"29","author":"LM Zaeck","year":"2023","unstructured":"Zaeck, L. M. et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat. Med. 29, 270\u2013278 (2023).","journal-title":"Nat. Med."},{"key":"68335_CR48","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.1016\/j.vaccine.2022.10.078","volume":"40","author":"L Priyamvada","year":"2022","unstructured":"Priyamvada, L. et al. Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo. Vaccine 40, 7321\u20137327 (2022).","journal-title":"Vaccine"},{"key":"68335_CR49","doi-asserted-by":"publisher","first-page":"e29728","DOI":"10.1002\/jmv.29728","volume":"96","author":"S Marchi","year":"2024","unstructured":"Marchi, S. et al. Evaluation of monkeypox- and vaccinia-virus neutralizing antibodies before and after smallpox vaccination: a sero-epidemiological study. J. Med. Virol. 96, e29728 (2024).","journal-title":"J. Med. Virol."},{"key":"68335_CR50","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.chom.2023.05.001","volume":"31","author":"M Hubert","year":"2023","unstructured":"Hubert, M. et al. Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals. Cell Host Microbe 31, 937\u2013948.e4 (2023).","journal-title":"Cell Host Microbe"},{"key":"68335_CR51","doi-asserted-by":"publisher","first-page":"126661","DOI":"10.1016\/j.vaccine.2024.126661","volume":"46","author":"SC Galetti","year":"2025","unstructured":"Galetti, S. C. et al. Historic smallpox vaccination and Mpox cross-reactive immunity: Evidence from healthcare workers with childhood and adulthood exposures. Vaccine 46, 126661 (2025).","journal-title":"Vaccine"},{"key":"68335_CR52","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41392-023-01574-6","volume":"8","author":"E Li","year":"2023","unstructured":"Li, E. et al. Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus. Signal Transduct. Target Ther. 8, 350 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"68335_CR53","first-page":"16","volume":"ume","author":"S Marchi","year":"2025","unstructured":"Marchi, S. et al. Correlation between microneutralization test and a multiplexed immunoassay for evaluation of monkeypox and vaccinia virus antibodies before and after smallpox vaccination. Front Immunol. ume, 16\u20132025 (2025).","journal-title":"Front Immunol."},{"key":"68335_CR54","doi-asserted-by":"crossref","unstructured":"Wayengera, M. et al. Mpox epidemics: a call to restore humanity\u2019s lost herd immunity to Orthopoxviruses. Viruses 17, (2025).","DOI":"10.3390\/v17091257"},{"key":"68335_CR55","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3390\/vaccines10122083","volume":"10","author":"P Satapathy","year":"2022","unstructured":"Satapathy, P. et al. Potentially asymptomatic infection of Monkeypox virus: A systematic review and meta-analysis. Vaccines (Basel) 10, 2083 (2022).","journal-title":"Vaccines (Basel)"},{"key":"68335_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33792-x","volume":"13","author":"A Abdullahi","year":"2022","unstructured":"Abdullahi, A. et al. SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. Nat. Commun. 13, 6131 (2022).","journal-title":"Nat. Commun."},{"key":"68335_CR57","doi-asserted-by":"publisher","unstructured":"Abdullahi, A. et al. SARS-CoV-2 infection imprints neutralising antibody responses in the absence of vaccination. ResearchSquare https:\/\/doi.org\/10.21203\/rs.3.rs-6347062\/v1 (2025).","DOI":"10.21203\/rs.3.rs-6347062\/v1"},{"key":"68335_CR58","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1038\/s41591-025-03820-6","volume":"31","author":"C Ruis","year":"2025","unstructured":"Ruis, C. et al. A systematic nomenclature for mpox viruses causing outbreaks with sustained human-to-human transmission. Nat. Med. 31, 2854\u20132858 (2025).","journal-title":"Nat. Med."},{"key":"68335_CR59","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.cell.2024.02.003","volume":"187","author":"MI Paredes","year":"2024","unstructured":"Paredes, M. I. et al. Underdetected dispersal and extensive local transmission drove the 2022 mpox epidemic. Cell 187, 1374\u20131386.e13 (2024).","journal-title":"Cell"},{"key":"68335_CR60","doi-asserted-by":"publisher","unstructured":"Figgins, M. D. & Bedford, T. Inferring variant-specific effective reproduction numbers from combined case and sequencing data. medRxiv 2021.12.09.21267544 https:\/\/doi.org\/10.1101\/2021.12.09.21267544 (2024).","DOI":"10.1101\/2021.12.09.21267544"},{"key":"68335_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46590-4","volume":"15","author":"G Guzzetta","year":"2024","unstructured":"Guzzetta, G. et al. The decline of the 2022 Italian mpox epidemic: Role of behavior changes and control strategies. Nat. Commun. 15, 2283 (2024).","journal-title":"Nat. Commun."},{"key":"68335_CR62","doi-asserted-by":"publisher","first-page":"e2305299121","DOI":"10.1073\/pnas.2305299121","volume":"121","author":"C Tran-Kiem","year":"2024","unstructured":"Tran-Kiem, C. & Bedford, T. Estimating the reproduction number and transmission heterogeneity from the size distribution of clusters of identical pathogen sequences. Proc. Natl. Acad. Sci. USA 121, e2305299121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68335_CR63","first-page":"D7","volume":"29","author":"DA Henderson","year":"2011","unstructured":"Henderson, D. A. The eradication of smallpox \u2013 An overview of the past. Future Vaccin. 29, D7\u2013D9 (2011).","journal-title":"Future Vaccin."},{"key":"68335_CR64","doi-asserted-by":"publisher","unstructured":"Crandell, J. et al. The impact of orthopoxvirus vaccination and Mpox infection on cross-protective immunity: a multicohort observational study. Lancet Microbe https:\/\/doi.org\/10.1016\/j.lanmic.2025.101098 (2025).","DOI":"10.1016\/j.lanmic.2025.101098"},{"key":"68335_CR65","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/S0140-6736(25)01203-6","volume":"405","author":"O Mitj\u00e0","year":"2025","unstructured":"Mitj\u00e0, O., Watson-Jones, D., Choi, E. M., Jalloh, M. B. & Sahr, F. Clade IIb mpox outbreak in Sierra Leone.  Lancet 405, 2274\u20132275 (2025).","journal-title":"Lancet"},{"key":"68335_CR66","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1086\/340517","volume":"185","author":"FA Ennis","year":"2002","unstructured":"Ennis, F. A., Cruz, J., Demkowicz, W. E. Jr, Rothman, A. L. & McClain, D. J. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-\u03b3-producing T cells after smallpox vaccination. J. Infect. Dis. 185, 1657\u20131659 (2002).","journal-title":"J. Infect. Dis."},{"key":"68335_CR67","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1086\/423851","volume":"190","author":"N Orr","year":"2004","unstructured":"Orr, N. et al. Clinical and immune responses after revaccination of israeli adults with the lister strain of vaccinia virus. J. Infect. Dis. 190, 1295\u20131302 (2004).","journal-title":"J. Infect. Dis."},{"key":"68335_CR68","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/nm917","volume":"9","author":"E Hammarlund","year":"2003","unstructured":"Hammarlund, E. et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med 9, 1131\u20131137 (2003).","journal-title":"Nat. Med"},{"key":"68335_CR69","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1086\/380460","volume":"38","author":"S-M Hsieh","year":"2004","unstructured":"Hsieh, S.-M., Pan, S.-C., Chen, S.-Y., Huang, P.-F. & Chang, S.-C. Age distribution for T cell reactivity to vaccinia virus in a healthy population. Clin. Infect. Dis. 38, 86\u201389 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"68335_CR70","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.amjmed.2008.08.019","volume":"121","author":"DD Taub","year":"2008","unstructured":"Taub, D. D. et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am. J. Med 121, 1058\u20131064 (2008).","journal-title":"Am. J. Med"},{"key":"68335_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48312-2","volume":"15","author":"R Zhao","year":"2024","unstructured":"Zhao, R. et al. Two noncompeting human neutralizing antibodies targeting MPXV B6 show protective effects against orthopoxvirus infections. Nat. Commun. 15, 4660 (2024).","journal-title":"Nat. Commun."},{"key":"68335_CR72","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/j.vaccine.2023.12.086","volume":"42","author":"FM Giorgi","year":"2024","unstructured":"Giorgi, F. M., Pozzobon, D., Di Meglio, A. & Mercatelli, D. Genomic and transcriptomic analysis of the recent Mpox outbreak. Vaccine 42, 1841\u20131849 (2024).","journal-title":"Vaccine"},{"key":"68335_CR73","doi-asserted-by":"crossref","unstructured":"Crossley, L. et al. Susceptibility and transmission of mpox virus infection in brown rats (Rattus norvegicus). J. Gen. Virol. 106, (2025).","DOI":"10.1099\/jgv.0.002125"},{"key":"68335_CR74","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/v15040905","volume":"15","author":"EA Falendysz","year":"2023","unstructured":"Falendysz, E. A., Lopera, J. G., Rocke, T. E. & Osorio, J. E. Monkeypox virus in animals: Current knowledge of viral transmission and pathogenesis in wild animal reservoirs and captive animal models. Viruses 15, 905 (2023).","journal-title":"Viruses"},{"key":"68335_CR75","doi-asserted-by":"publisher","first-page":"105372","DOI":"10.1016\/j.meegid.2022.105372","volume":"105","author":"D Forni","year":"2022","unstructured":"Forni, D., Cagliani, R., Molteni, C., Clerici, M. & Sironi, M. Monkeypox virus: the changing facets of a zoonotic pathogen. Infect., Genet. Evolution 105, 105372 (2022).","journal-title":"Infect., Genet. Evolution"},{"key":"68335_CR76","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41564-020-0706-0","volume":"5","author":"LV Patrono","year":"2020","unstructured":"Patrono, L. V. et al. Monkeypox virus emergence in wild chimpanzees reveals distinct clinical outcomes and viral diversity. Nat. Microbiol. 5, 955\u2013965 (2020).","journal-title":"Nat. Microbiol."},{"key":"68335_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00113-z","volume":"11","author":"J Clark","year":"2021","unstructured":"Clark, J. et al. Domestic risk factors for increased rodent abundance in a Lassa fever endemic region of rural Upper Guinea. Sci. Rep. 11, 20698 (2021).","journal-title":"Sci. Rep."},{"key":"68335_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/srep25280","volume":"6","author":"A Olayemi","year":"2016","unstructured":"Olayemi, A. et al. New hosts of the lassa virus. Sci. Rep. 6, 25280 (2016).","journal-title":"Sci. Rep."},{"key":"68335_CR79","doi-asserted-by":"publisher","first-page":"974","DOI":"10.4269\/ajtmh.20-1160","volume":"105","author":"DE Agbonlahor","year":"2021","unstructured":"Agbonlahor, D. E., Akpede, G. O., Happi, C. T. & Tomori, O. 52 years of lassa fever outbreaks in Nigeria, 1969\u20132020: an epidemiologic analysis of the temporal and spatial trends. Am. J. Trop. Med Hyg. 105, 974\u2013985 (2021).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"68335_CR80","doi-asserted-by":"publisher","first-page":"935","DOI":"10.4269\/ajtmh.16-0675","volume":"96","author":"J Bonwitt","year":"2017","unstructured":"Bonwitt, J. et al. At Home with Mastomys and Rattus: Human-Rodent Interactions and Potential for Primary Transmission of Lassa Virus in Domestic Spaces.  Am. Soc. Tropical Med. Hyg. 96, 935\u2013943 (2017).","journal-title":"Am. Soc. Tropical Med. Hyg."},{"key":"68335_CR81","doi-asserted-by":"publisher","first-page":"e1962","DOI":"10.1016\/S2214-109X(24)00379-6","volume":"12","author":"P Doohan","year":"2024","unstructured":"Doohan, P. et al. Lassa fever outbreaks, mathematical models, and disease parameters: a systematic review and meta-analysis. Lancet Glob. Health 12, e1962\u2013e1972 (2024).","journal-title":"Lancet Glob. Health"},{"key":"68335_CR82","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf308","author":"J Mari\u00ebn","year":"2025","unstructured":"Mari\u00ebn, J. et al. Serosurveillance Identifies an Endemic Hotspot of Lassa Fever in Faranah, Upper Guinea. J. Infect. Dis. jiaf308 https:\/\/doi.org\/10.1093\/infdis\/jiaf308 (2025).","journal-title":"J. Infect. Dis. jiaf308"},{"key":"68335_CR83","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41579-022-00789-8","volume":"21","author":"RF Garry","year":"2023","unstructured":"Garry, R. F. Lassa fever - the road ahead. Nat. Rev. Microbiol. 21, 87\u201396 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"68335_CR84","doi-asserted-by":"publisher","first-page":"1522733","DOI":"10.3389\/fpubh.2025.1522733","volume":"13","author":"BB Herrera","year":"2025","unstructured":"Herrera, B. B. et al. Pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2 among female sex workers in Dakar, Senegal. Front Public Health 13, 1522733 (2025).","journal-title":"Front Public Health"},{"key":"68335_CR85","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/23744235.2025.2449902","volume":"57","author":"G Ceccarelli","year":"2025","unstructured":"Ceccarelli, G., Francesco, B., Fabio, S., Marta, G. & Ciccozzi, M. Helminthiasis and mpox vaccination: challenges in Sub-Saharan Africa. Infect. Dis. 57, 301\u2013303 (2025).","journal-title":"Infect. Dis."},{"key":"68335_CR86","doi-asserted-by":"publisher","first-page":"e20597","DOI":"10.1371\/journal.pone.0020597","volume":"6","author":"ME Cohen","year":"2011","unstructured":"Cohen, M. E., Xiao, Y., Eisenberg, R. J., Cohen, G. H. & Isaacs, S. N. Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors. PLoS ONE 6, e20597 (2011).","journal-title":"PLoS ONE"},{"key":"68335_CR87","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2401931","volume":"13","author":"Z Ren","year":"2024","unstructured":"Ren, Z. et al. Identification of mpox M1R and B6R monoclonal and bispecific antibodies that efficiently neutralize authentic mpox virus. Emerg. Microbes Infect. 13, 2401931 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"68335_CR88","first-page":"e02456","volume":"13","author":"Laidlaw Stephen","year":"2025","unstructured":"Laidlaw Stephen et al. Detection of mpox and other orthopoxviruses using a lateral flow device as a point-of-care diagnostic. Microbiol Spectr. 13, e02456\u201324 (2025).","journal-title":"Microbiol Spectr."},{"key":"68335_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57647-3","volume":"16","author":"ML Cavuto","year":"2025","unstructured":"Cavuto, M. L. et al. Portable molecular diagnostic platform for rapid point-of-care detection of mpox and other diseases. Nat. Commun. 16, 2875 (2025).","journal-title":"Nat. Commun."},{"key":"68335_CR90","doi-asserted-by":"publisher","first-page":"ofy251","DOI":"10.1093\/ofid\/ofy251","volume":"5","author":"A Abdullahi","year":"2018","unstructured":"Abdullahi, A. et al. Hepatitis B Virus (HBV) infection and re-activation during Nucleos(t)ide reverse transcriptase inhibitor\u2013sparing antiretroviral therapy in a high\u2013HBV endemicity setting. Open Forum Infect. Dis. 5, ofy251 (2018).","journal-title":"Open Forum Infect. Dis."},{"key":"68335_CR91","doi-asserted-by":"publisher","first-page":"e29134","DOI":"10.1002\/jmv.29134","volume":"95","author":"JL Yates","year":"2023","unstructured":"Yates, J. L. et al. Development of a novel serological assay for the detection of mpox infection in vaccinated populations. J. Med Virol. 95, e29134 (2023).","journal-title":"J. Med Virol."},{"key":"68335_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40756-8","volume":"13","author":"SA Kayuni","year":"2023","unstructured":"Kayuni, S. A. et al. Prospective pilot study on the relationship between seminal HIV-1 shedding and genital schistosomiasis in men receiving antiretroviral therapy along Lake Malawi. Sci. Rep. 13, 14154 (2023).","journal-title":"Sci. Rep."},{"key":"68335_CR93","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1093\/jac\/dkad195","volume":"78","author":"A Abdullahi","year":"2023","unstructured":"Abdullahi, A. et al. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort. J. Antimicrobial Chemother. 78, 2000\u20132007 (2023).","journal-title":"J. Antimicrobial Chemother."},{"key":"68335_CR94","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jac\/dkad386","volume":"79","author":"A Abdullahi","year":"2024","unstructured":"Abdullahi, A. et al. A detailed characterization of drug resistance during darunavir\/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance. J. Antimicrobial Chemother. 79, 339\u2013348 (2024).","journal-title":"J. Antimicrobial Chemother."},{"key":"68335_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-06536-2","volume":"15","author":"A Salako","year":"2025","unstructured":"Salako, A. et al. Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: a randomized non-inferiority trial. Sci. Rep. 15, 27614 (2025).","journal-title":"Sci. Rep."},{"key":"68335_CR96","unstructured":"FMOH. Nigeria: National Guidelines for HIV Counselling and Testing. https:\/\/www.medbox.org\/document\/nigeria-national-guidelines-for-hiv-counselling-and-testing (2011)."},{"key":"68335_CR97","doi-asserted-by":"publisher","first-page":"e0001077","DOI":"10.1371\/journal.pgph.0001077","volume":"2","author":"NC Iriemenam","year":"2022","unstructured":"Iriemenam, N. C. et al. Evaluation of the Nigeria national HIV rapid testing algorithm. PLOS Glob. Public Health 2, e0001077 (2022).","journal-title":"PLOS Glob. Public Health"},{"key":"68335_CR98","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/S1473-3099(23)00352-3","volume":"23","author":"H Cohn","year":"2023","unstructured":"Cohn, H. et al. Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study. Lancet Infect. Dis. 23, 1302\u20131312 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"68335_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41587-x","volume":"14","author":"AD Otter","year":"2023","unstructured":"Otter, A. D. et al. Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals. Nat. Commun. 14, 5948 (2023).","journal-title":"Nat. Commun."},{"key":"68335_CR100","doi-asserted-by":"crossref","unstructured":"Jones, S. et al. Assessment of MpoxPlex, a high-throughput and multiplexed immunoassay: a diagnostic accuracy study. Lancet Microbe 6, (2025).","DOI":"10.1016\/j.lanmic.2024.100987"},{"key":"68335_CR101","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1016\/S2666-5247(23)00365-8","volume":"5","author":"RF Fantin","year":"2024","unstructured":"Fantin, R. F. & Coelho, C. H. Human antibody responses to circulating monkeypox virus emphasise the need for the first mpox-specific vaccine. Lancet Microbe 5, e204\u2013e205 (2024).","journal-title":"Lancet Microbe"},{"key":"68335_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62064-7","volume":"16","author":"LM Masirika","year":"2025","unstructured":"Masirika, L. M. et al. Serological evidence of clade Ib Mpox transmission by sex workers and within household in South Kivu, DRC. Nat. Commun. 16, 7056 (2025).","journal-title":"Nat. Commun."},{"key":"68335_CR103","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41594-020-0478-5","volume":"27","author":"X Xiong","year":"2020","unstructured":"Xiong, X. et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat. Struct. Mol. Biol. 27, 934\u2013941 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"68335_CR104","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/infdis\/jis367","volume":"206","author":"DC Montefiori","year":"2012","unstructured":"Montefiori, D. C. et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206, 431\u2013441 (2012).","journal-title":"J. Infect. Dis."},{"key":"68335_CR105","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1198\/sbr.2009.0008","volume":"1","author":"Y Huang","year":"2009","unstructured":"Huang, Y., Gilbert, P. B., Montefiori, D. C. & Self, S. G. Simultaneous evaluation of the magnitude and breadth of a left- and right-censored multivariate response.  Application HIV Vaccin. Dev. Stat. Biopharm. Res. 1, 81\u201391 (2009).","journal-title":"Application HIV Vaccin. Dev. Stat. Biopharm. Res."},{"key":"68335_CR106","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1086\/654816","volume":"202","author":"P Gilbert","year":"2010","unstructured":"Gilbert, P. et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 202, 595\u2013605 (2010).","journal-title":"J. Infect. Dis."},{"key":"68335_CR107","doi-asserted-by":"publisher","first-page":"105438","DOI":"10.1016\/j.ebiom.2024.105438","volume":"110","author":"S Einhauser","year":"2024","unstructured":"Einhauser, S. et al. Longitudinal effects of SARS-CoV-2 breakthrough infection on imprinting of neutralizing antibody responses. EBioMedicine 110, 105438 (2024).","journal-title":"EBioMedicine"},{"key":"68335_CR108","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/molbev\/mss265","volume":"30","author":"MS Gill","year":"2013","unstructured":"Gill, M. S. et al. Improving Bayesian population dynamics inference: a coalescent-based model for multiple loci. Mol. Biol. Evol. 30, 713\u2013724 (2013).","journal-title":"Mol. Biol. Evol."},{"key":"68335_CR109","doi-asserted-by":"publisher","first-page":"890","DOI":"10.4269\/ajtmh.23-0179","volume":"109","author":"A Abdullahi","year":"2023","unstructured":"Abdullahi, A. et al. Performance of SARS COV-2 IgG Anti-N as an independent marker of exposure to SARS COV-2 in an unvaccinated west African population. Am. J. Trop. Med Hyg. 109, 890\u2013894 (2023).","journal-title":"Am. J. Trop. Med Hyg."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68335-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68335-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68335-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:02:59Z","timestamp":1768903379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68335-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68335"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68335-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"482"}}